Everest Organics Ltd gets Korea Drug Master File approval for Rabeprazole Sodium API

Everest Organics Limited ("Company") has obtained Korea Drug Master File (KDMF) approval in the Month of February 2025 for its Rabeprazole Sodium API.

The Rabeprazole Sodium API is primarily used to treat conditions related to excessive stomach acid production, including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome, as it acts as a proton pump inhibitor (PPI) by significantly reducing the amount of acid produced in the stomach; essentially helping to heal ulcers and alleviate symptoms like heartburn and acid reflux.

The Company is now able to export its Rabeprazole Sodium API to the South Korean market.

Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs. 256.45 as compared to the previous close of Rs. 244.95. The total number of shares traded during the day was 20471 in over 53 trades.

The stock hit an intraday high of Rs. 257.15 and intraday low of 232.75. The net turnover during the day was Rs. 5209826.00.

Source : Equity Bulls

Keywords

EVERESTORGANICS INE334C01029 Pharmaceuticals KDMF Approval Korea RabeprazoleSodium API